| ENANTA PHARMA.INC. DL-,01 |
| USA |
| Gesundheit |
| US29251M1062 / A1T7BJ |
| 9EP (Frankfurt) / ENTA (NASDAQ) |
| FRA:9EP, ETR:9EP, 9EP:GR, NASDAQ:ENTA |
| - |
| https://www.enanta.com/ |
|
Enanta Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery and development of small molecule drugs. The primary focus of the company is on creating innovative treatments for viral infections and liver diseases. Enanta has a pro..
>Volltext.. |
| 326.06 Mio. EUR |
| 332.31 Mio. EUR |
| 58.03 Mio. EUR |
| -59.02 Mio. EUR |
| -61.97 Mio. EUR |
| -2.78 EUR |
| 167.36 Mio. EUR |
| 32.43 Mio. EUR |
| -12.28 Mio. EUR |
| 4.16 |
| -11.34% |
| 39.91% |
| - |
| - |
| - |
| - |
| ENANTA |
| 05.04.26 |